dc.contributor
Institut Català de la Salut
dc.contributor
[Fernández Montes A] Medical Oncology Department, Complexo Hospitalario Universitario, Ourense (CHUO), Ourense, Spain. [Alonso V] Medical Oncology Department, Hospital Universitario Miguel Servet, Saragossa, Spain. [Aranda E] Medical Oncology Department, Hospital Universitario Reina Sofía, Córdoba, Spain. [Élez E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [García Alfonso P] Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain. [Grávalos C] Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Fernández Montes, Ana
dc.contributor.author
Alonso, Vicente
dc.contributor.author
Aranda Aguilar, Enrique
dc.contributor.author
Grávalos, Cristina
dc.contributor.author
Elez, Elena
dc.contributor.author
García-Alfonso, Pilar
dc.date.accessioned
2025-10-24T10:28:13Z
dc.date.available
2025-10-24T10:28:13Z
dc.date.issued
2023-09-05T11:57:55Z
dc.date.issued
2023-09-05T11:57:55Z
dc.identifier
Fernández Montes A, Alonso V, Aranda E, Élez E, García Alfonso P, Grávalos C, et al. SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022). Clin Transl Oncol. 2023 Sep;25:2718–31.
dc.identifier
https://hdl.handle.net/11351/10232
dc.identifier
10.1007/s12094-023-03199-1
dc.identifier
000980817100001
dc.identifier.uri
https://hdl.handle.net/11351/10232
dc.description.abstract
Colorectal cancer; Metastatic disease; Systemic treatment
dc.description.abstract
Càncer colorectal; Malaltia metastàtica; Tractament sistèmic
dc.description.abstract
Cáncer colorrectal; Enfermedad metastásica; Tratamiento sistémico
dc.description.abstract
Colorectal cancer (CRC) is the second leading cause of cancer deaths in Spain. Metastatic disease is present in 15–30% of patients at diagnosis and up to 20–50% of those with initially localized disease eventually develop metastases. Recent scientific knowledge acknowledges that this is a clinically and biologically heterogeneous disease. As treatment options increase, prognosis for individuals with metastatic disease has steadily improved over recent decades. Disease management should be discussed among experienced, multidisciplinary teams to select the most appropriate systemic treatment (chemotherapy and targeted agents) and to integrate surgical or ablative procedures, when indicated. Clinical presentation, tumor sidedness, molecular profile, disease extension, comorbidities, and patient preferences are key factors when designing a customized treatment plan. These guidelines seek to provide succinct recommendations for managing metastatic CRC.
dc.format
application/pdf
dc.relation
Clinical and Translational Oncology;25
dc.relation
https://doi.org/10.1007/s12094-023-03199-1
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Recte - Càncer - Tractament
dc.subject
Còlon - Càncer - Tractament
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms
dc.subject
PUBLIC HEALTH::Health Care (Public Health)::Delivery of Health Care::Disease Management
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales
dc.subject
SALUD PÚBLICA::atención a la salud (salud pública)::prestación sanitaria::tratamiento de las enfermedades
dc.title
SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022)
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
